Generic Name:
brexucabtagene autoleucel
Project Status:
Active
Therapeutic Area:
Mantle cell lymphoma
Manufacturer:
Gilead Sciences Canada Inc.
Brand Name:
Tecartus
Project Line:
Reimbursement Review
Project Number:
PG0219-000
Tumour Type:
Lymphoma
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have
received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.